Cargando…

Serum fatty acid profile in psoriasis and its comorbidity

Psoriasis is a chronic inflammatory skin disease that is accompanied by metabolic disturbances and cardio-metabolic disorders. Fatty acids (FAs) might be a link between psoriasis and its comorbidity. The aim of the study was to evaluate serum concentrations of FAs and to investigate their associatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Myśliwiec, Hanna, Baran, Anna, Harasim-Symbor, Ewa, Myśliwiec, Piotr, Milewska, Anna Justyna, Chabowski, Adrian, Flisiak, Iwona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486566/
https://www.ncbi.nlm.nih.gov/pubmed/28585093
http://dx.doi.org/10.1007/s00403-017-1748-x
_version_ 1783246279471529984
author Myśliwiec, Hanna
Baran, Anna
Harasim-Symbor, Ewa
Myśliwiec, Piotr
Milewska, Anna Justyna
Chabowski, Adrian
Flisiak, Iwona
author_facet Myśliwiec, Hanna
Baran, Anna
Harasim-Symbor, Ewa
Myśliwiec, Piotr
Milewska, Anna Justyna
Chabowski, Adrian
Flisiak, Iwona
author_sort Myśliwiec, Hanna
collection PubMed
description Psoriasis is a chronic inflammatory skin disease that is accompanied by metabolic disturbances and cardio-metabolic disorders. Fatty acids (FAs) might be a link between psoriasis and its comorbidity. The aim of the study was to evaluate serum concentrations of FAs and to investigate their association with the disease activity, markers of inflammation and possible involvement in psoriatic comorbidity: obesity, type 2 diabetes and hypertension. We measured 14 total serum fatty acids content and composition by gas–liquid chromatography and flame-ionization detector after direct in situ transesterification in 85 patients with exacerbated plaque psoriasis and in 32 healthy controls. FAs were grouped according to their biologic properties to saturated FA (SFA), unsaturated FA (UFA), monounsaturated FA (MUFA), n-3 polyunsaturated FA (n-3 PUFA) and n-6 PUFA. Generally, patients characteristic included: Psoriasis Area and Severity Index (PASI), Body Mass Index, inflammatory and biochemical markers, lipid profile and presence of psoriatic comorbidity. We have observed highly abnormal FAs pattern in psoriatic patients both with and without obesity compared to the control group. We have demonstrated association of PASI with low levels of circulating DHA, n-3 PUFA (p = 0.044 and p = 0.048, respectively) and high percent of MUFA (p = 0.024) in the non-obese psoriatic group. The SFA/UFA ratio increased with the duration of the disease (p = 0.03) in all psoriatic patients. These findings indicate abnormal FAs profile in psoriasis which may reflect metabolic disturbances and might play a role in the psoriatic comorbidity.
format Online
Article
Text
id pubmed-5486566
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-54865662017-07-17 Serum fatty acid profile in psoriasis and its comorbidity Myśliwiec, Hanna Baran, Anna Harasim-Symbor, Ewa Myśliwiec, Piotr Milewska, Anna Justyna Chabowski, Adrian Flisiak, Iwona Arch Dermatol Res Original Paper Psoriasis is a chronic inflammatory skin disease that is accompanied by metabolic disturbances and cardio-metabolic disorders. Fatty acids (FAs) might be a link between psoriasis and its comorbidity. The aim of the study was to evaluate serum concentrations of FAs and to investigate their association with the disease activity, markers of inflammation and possible involvement in psoriatic comorbidity: obesity, type 2 diabetes and hypertension. We measured 14 total serum fatty acids content and composition by gas–liquid chromatography and flame-ionization detector after direct in situ transesterification in 85 patients with exacerbated plaque psoriasis and in 32 healthy controls. FAs were grouped according to their biologic properties to saturated FA (SFA), unsaturated FA (UFA), monounsaturated FA (MUFA), n-3 polyunsaturated FA (n-3 PUFA) and n-6 PUFA. Generally, patients characteristic included: Psoriasis Area and Severity Index (PASI), Body Mass Index, inflammatory and biochemical markers, lipid profile and presence of psoriatic comorbidity. We have observed highly abnormal FAs pattern in psoriatic patients both with and without obesity compared to the control group. We have demonstrated association of PASI with low levels of circulating DHA, n-3 PUFA (p = 0.044 and p = 0.048, respectively) and high percent of MUFA (p = 0.024) in the non-obese psoriatic group. The SFA/UFA ratio increased with the duration of the disease (p = 0.03) in all psoriatic patients. These findings indicate abnormal FAs profile in psoriasis which may reflect metabolic disturbances and might play a role in the psoriatic comorbidity. Springer Berlin Heidelberg 2017-06-05 2017 /pmc/articles/PMC5486566/ /pubmed/28585093 http://dx.doi.org/10.1007/s00403-017-1748-x Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Paper
Myśliwiec, Hanna
Baran, Anna
Harasim-Symbor, Ewa
Myśliwiec, Piotr
Milewska, Anna Justyna
Chabowski, Adrian
Flisiak, Iwona
Serum fatty acid profile in psoriasis and its comorbidity
title Serum fatty acid profile in psoriasis and its comorbidity
title_full Serum fatty acid profile in psoriasis and its comorbidity
title_fullStr Serum fatty acid profile in psoriasis and its comorbidity
title_full_unstemmed Serum fatty acid profile in psoriasis and its comorbidity
title_short Serum fatty acid profile in psoriasis and its comorbidity
title_sort serum fatty acid profile in psoriasis and its comorbidity
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486566/
https://www.ncbi.nlm.nih.gov/pubmed/28585093
http://dx.doi.org/10.1007/s00403-017-1748-x
work_keys_str_mv AT mysliwiechanna serumfattyacidprofileinpsoriasisanditscomorbidity
AT barananna serumfattyacidprofileinpsoriasisanditscomorbidity
AT harasimsymborewa serumfattyacidprofileinpsoriasisanditscomorbidity
AT mysliwiecpiotr serumfattyacidprofileinpsoriasisanditscomorbidity
AT milewskaannajustyna serumfattyacidprofileinpsoriasisanditscomorbidity
AT chabowskiadrian serumfattyacidprofileinpsoriasisanditscomorbidity
AT flisiakiwona serumfattyacidprofileinpsoriasisanditscomorbidity